Caught off guard: the reality of incidental prostate cancer diagnosis

To ensure every man with prostate cancer has the best chance of a long, healthy life, we need precise and powerful treatments that can save and extend men’s lives.

In the past year, this goal moved closer to reality thanks to the discovery of better, more effective treatments – made possible with your support.

However, there's still more work to be done to ensure these treatments make it into the hands of everyone who needs them.

Let’s look back at some of the biggest advances from the past year, and what we still need to do to ensure every man receives the personalised care he deserves.

Incidental diagnosis: insights from Dr. Noel

Last Spring, it was announced that olaparib, a drug that kills prostate cancer cells with a particular genetic weakness, can now be given to eligible men across the UK.

Hundreds of men will now benefit from the drug, which has been shown to help men live several months longer on average.

Originally developed and approved to treat women with breast or ovarian cancer, olaparib can kill cancer cells that have faulty DNA repair systems caused by a mutation in their BRCA genes.

Thanks to your support, we were able to fund research that later found the treatment to be effective in prostate cancer, for men whose cancer also has these faulty repair mechanisms.

And now, following this research, men across the UK can receive treatment based on the genetic make-up of their prostate cancer.

The earlier the diagnosis, the better

Olaparib’s approval finally moves us away from a ‘one-size-fits-all' approach to prostate cancer and towards a future where every man gets a treatment tailored to him.

But not every man can benefit from olaparib – only some men have the right genetics.

So, to ensure that every man can benefit from this future, we need even more treatments that factor in each man’s unique biology.

That’s why, in the coming year, we’ll be funding even more research into the next generation of tests and treatments.

The projects will investigate all aspects of prostate cancer, from the underlying biology that drives it, to the weaknesses that could uncover new paths to treating it.

Last year, for example, we began funding Dr Jennifer Munkley at Newcastle University and Dr Benjamin Schumann at Imperial College London to zero in on sugar molecules found on the surface of prostate cancer cells that cause tumours to grow and spread.

Donate today